IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v16y2025i1d10.1038_s41467-025-58186-7.html
   My bibliography  Save this article

Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC

Author

Listed:
  • Kentaro Tanaka

    (Kyushu University
    Kagoshima University
    Kagoshima University)

  • Jun Sugisaka

    (Sendai Kousei Hospital)

  • Yoshimasa Shiraishi

    (Kyushu University)

  • Yasutaka Watanabe

    (Saitama Cancer Center)

  • Haruko Daga

    (Osaka City General Hospital)

  • Koichi Azuma

    (Kurume University School of Medicine)

  • Kazumi Nishino

    (Osaka International Cancer Institute)

  • Masahide Mori

    (NHO Osaka Toneyama Medical Center)

  • Takayo Ota

    (Izumi City General Hospital)

  • Haruhiro Saito

    (Kanagawa Cancer Center)

  • Akito Hata

    (Kobe Minimally Invasive Cancer Center)

  • Tadashi Sakaguchi

    (Matsusaka Municipal Hospital)

  • Toshiyuki Kozuki

    (NHO Shikoku Cancer Center)

  • Hiroaki Akamatsu

    (Wakayama Medical University)

  • Hirotaka Matsumoto

    (Hyogo Prefectural Amagasaki General Medical Center)

  • Motoko Tachihara

    (Kobe University Graduate School of Medicine)

  • Kazushige Wakuda

    (Shizuoka Cancer Center Hospital)

  • Yuki Sato

    (Kobe City Medical Center General Hospital)

  • Tomohiro Ozaki

    (Kishiwada City Hospital)

  • Yuko Tsuchiya-Kawano

    (Kitakyushu Municipal Medical Center)

  • Nobuyuki Yamamoto

    (NHO Shikoku Cancer Center)

  • Kazuhiko Nakagawa

    (Kindai University Faculty of Medicine)

  • Isamu Okamoto

    (Kyushu University)

Abstract

Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers have not been elucidated. We report here a preplanned analysis in the previously reported APPLE study, a phase 3 trial evaluating the efficacy of the bevacizumab in combination with atezolizumab, plus platinum chemotherapy in metastatic, nonsquamous non-small cell lung cancer (NSCLC). We investigated the correlation of serum VEGF-A and its isoforms at baseline with treatment response by using an enzyme-linked immunosorbent assay. We reveal that the addition of bevacizumab significantly improves the progression-free survival in patients with the low VEGF-A level. Our results demonstrate that measuring serum VEGF-A or its isoforms may identify NSCLC patients who are likely to benefit from the addition of bevacizumab to immunotherapy. These assays are easy to measure and have significant potential for further clinical development.

Suggested Citation

  • Kentaro Tanaka & Jun Sugisaka & Yoshimasa Shiraishi & Yasutaka Watanabe & Haruko Daga & Koichi Azuma & Kazumi Nishino & Masahide Mori & Takayo Ota & Haruhiro Saito & Akito Hata & Tadashi Sakaguchi & T, 2025. "Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC," Nature Communications, Nature, vol. 16(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58186-7
    DOI: 10.1038/s41467-025-58186-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-025-58186-7
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-025-58186-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-58186-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.